Topical insulin drops: successful treatment for refractory persistent corneal epithelial defects

Article

The use of topical insulin eye drops led to a successful resolution of PEDs in 9 of 11 cases in the study.

A doctor's gloved hands administer eye drops in a female patient's eye. Image credit: ©rh2010 – stock.adobe.com

Throughout the study, the insulin eye drops were instilled 4 times/day. Image credit: ©rh2010 – stock.adobe.com

A research team in the United Kingdom reported that topical insulin eye drops resolved refractory persistent epithelial defects (PEDs) in 9 of 11 cases in which they were tested.1 Shafi Balal, MD, was the first study author from Moorfields Eye Hospital and the UCL Institute of Ophthalmology, both in London.

The authors evaluated this treatment approach in a prospective, single-center case series from March 2020 to September 2021. The investigators explained that all patients were prescribed insulin eye drops for refractory PEDs that failed to achieve resolution of their PEDs despite receiving maximal standard medical treatment, including serum eye drops. The insulin eye drops were instilled 4 times/day. The patients were evaluated at 2-week intervals by full slit-lamp examination and serial anterior segment photography. The primary end point was resolution of the epithelial defects.

The study included 11 eyes of 10 patients (mean age, 45.4 years) that were treated with insulin eye drops. The mean follow-up was 195.7 ± 114.3 days after re-epithelization. The most common cause of the PEDs was chemical injury (n = 5, 60%). The mean size of the PED at baseline was 41.3 ± 55.2 mm2.

The authors reported that 9 of the 11 eyes (82%) fully re-epithelized in a mean time of 62.3 ± 34.6 days (range, 14–112). Of the remaining 2 patients, the PED decreased in size from 12.25 mm2 to 4.5 mm2 and 1 did not respond. Among the patients who achieved full re-epithelization, the defects did not recur.

“This study showed that the use of topical insulin eye drops led to a successful resolution of PEDs in 9 of 11 cases. We demonstrate the use of insulin for closure of PEDs in chemical eye injuries. Larger controlled studies are required to further evaluate this novel therapy,” the authors commented.

Reference

1. Balal S, Din N, Ashton C, Ahmad S. Healing of chemical injury–related persistent corneal epithelial defects with topical insulin. Cornea. 2023;42:1000-1004; doi:10.1097/ICO.0000000000003145

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.